SCHEMBL4859199

SCHEMBL4859199

CC(C)(O)C(C)(C)c1ccc2c(c1)NC(=O)c1ccc(B3OC(C)(C)C(C)(C)O3)cc1N2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 15/20 0.45
HIF1A Q16665 1/20 0.38
IKBKB O14920 1/20 0.35
PRMT5 O14744 2/20 0.35
WDR77 Q9BQA1 2/20 0.35
CSNK1G1 Q9HCP0 1/20 0.34
PDPK1 O15530 1/20 0.33
ROCK2 O75116 1/20 0.33
RPS6KA5 O75582 1/20 0.33
MAP4K4 O95819 1/20 0.33
CHEK2 O96017 1/20 0.33
CDK1 P06493 1/20 0.33
PIM1 P11309 1/20 0.33
RPS6KB1 P23443 1/20 0.33
CDK2 P24941 1/20 0.33
AKT2 P31751 1/20 0.33
MAPKAPK2 P49137 1/20 0.33
CDK8 P49336 1/20 0.33
GSK3A P49840 1/20 0.33
GSK3B P49841 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4855119 0.87 CHEK1 (0.52) CHEK1HIF1AIKBKBPRMT5WDR77
SCHEMBL4850599 0.87 CHEK1 (0.52) CHEK1HIF1AIKBKBPRMT5WDR77
SCHEMBL4850289 0.84 CHEK1 (0.45) CHEK1HIF1AIKBKBPRMT5WDR77
SCHEMBL4853578 0.81 ACVR1 (0.49) CHEK1CSNK1G1PDPK1ROCK2MAP4K4
SCHEMBL4857019 0.80 CHEK1 (0.53) CHEK1PRMT5WDR77CSNK1G1PDPK1
SCHEMBL4850794 0.79 CHEK1 (0.55) CHEK1CSNK1G1KDR
SCHEMBL4858753 0.79 CHEK1 (0.41) CHEK1
SCHEMBL4855604 0.77 CHEK1 (0.46) CHEK1HIF1ACHEK2AURKB
SCHEMBL4853670 0.74 CHEK1 (0.68) CHEK1IKBKBPDPK1CHEK2RPS6KB1
SCHEMBL4856016 0.74 CHEK1 (0.49) CHEK1HIF1AROCK2CHEK2GSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 CHEK1 38/4885HIF1A 3126/4885IKBKB 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.